Complete remission of peritoneal dissemination of colon cancer by alternate‑day S‑1 and oxaliplatin plus bevacizumab treatment and maintenance chemotherapy comprising alternate‑day S‑1 plus bevacizumab: A case report

  • Authors:
    • Nobuhiro Nitori
    • Ayu Kato
    • Tomoaki Deguchi
    • Jumpei Nakadai
    • Ayako Tada
    • Makoto Takahashi
    • Rumiko Umeda
    • Naoteru Miyata
    • Mikinori Kataoka
    • Tomohisa Kadomura
    • Hajime Higuchi
    • Hirotoshi Ebinuma
    • Atsushi Kato
    • Takashi Hatori
    • Yoshifumi Ikeda
    • Masaru Miyazaki
  • View Affiliations

  • Published online on: December 11, 2018     https://doi.org/10.3892/mco.2018.1791
  • Pages: 270-274
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

A 56‑year‑old man diagnosed with sigmoid colon cancer underwent sigmoid colectomy. Nine months later, his serum carcinoembryonic antigen (CEA) level had increased, and the diagnosis of recurrent peritoneal dissemination was made based on positron emission tomography/computed tomography (PET/CT) findings. Although systemic chemotherapy comprising S‑1 and oxaliplatin (SOX) plus bevacizumab was initiated, severe diarrhea occurred on day 4 of the second cycle despite reduction in S‑1 dose. By changing the daily oral intake schedule for S‑1 to an alternate‑day intake from the third cycle (modified SOX plus bevacizumab), the patient was able to continue undergoing chemotherapy without any adverse gastrointestinal effects. All tumors disappeared after four cycles, and the patients received eight cycles of modified SOX plus bevacizumab followed by maintenance chemotherapy comprising alternate‑day S‑1 plus bevacizumab. Maintenance chemotherapy was discontinued after 17 cycles owing to adverse events, including thrombocytopenia, corneal and lacrimal duct disorders, and hyperbilirubinemia. The patient has been radiographically confirmed to be in remission for 5 years without any recurrence, and his serum CEA level has been within normal range for >3 years. To conclude, compared with the conventional consecutive treatment, alternate‑day SOX plus bevacizumab treatment may reduce the adverse effects of these chemotherapeutic drugs.
View Figures
View References

Related Articles

Journal Cover

February 2019
Volume 10 Issue 2

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Nitori, N., Kato, A., Deguchi, T., Nakadai, J., Tada, A., Takahashi, M. ... Miyazaki, M. (2019). Complete remission of peritoneal dissemination of colon cancer by alternate‑day S‑1 and oxaliplatin plus bevacizumab treatment and maintenance chemotherapy comprising alternate‑day S‑1 plus bevacizumab: A case report. Molecular and Clinical Oncology, 10, 270-274. https://doi.org/10.3892/mco.2018.1791
MLA
Nitori, N., Kato, A., Deguchi, T., Nakadai, J., Tada, A., Takahashi, M., Umeda, R., Miyata, N., Kataoka, M., Kadomura, T., Higuchi, H., Ebinuma, H., Kato, A., Hatori, T., Ikeda, Y., Miyazaki, M."Complete remission of peritoneal dissemination of colon cancer by alternate‑day S‑1 and oxaliplatin plus bevacizumab treatment and maintenance chemotherapy comprising alternate‑day S‑1 plus bevacizumab: A case report". Molecular and Clinical Oncology 10.2 (2019): 270-274.
Chicago
Nitori, N., Kato, A., Deguchi, T., Nakadai, J., Tada, A., Takahashi, M., Umeda, R., Miyata, N., Kataoka, M., Kadomura, T., Higuchi, H., Ebinuma, H., Kato, A., Hatori, T., Ikeda, Y., Miyazaki, M."Complete remission of peritoneal dissemination of colon cancer by alternate‑day S‑1 and oxaliplatin plus bevacizumab treatment and maintenance chemotherapy comprising alternate‑day S‑1 plus bevacizumab: A case report". Molecular and Clinical Oncology 10, no. 2 (2019): 270-274. https://doi.org/10.3892/mco.2018.1791